Skip to main content

Table 3 Demographic and anthropometric data, body composition, laboratorial findings, juvenile dermatomyositis (JDM) scores and treatment in JDM patients with and without gingivitis

From: Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?

Variables

JDM with gingivitis (GBI > 25%, n = 12)

JDM without gingivitis (GBI ≤ 25%, n = 12)

p

Demographic data

 Current age, years

12.4 (8.3–18.4)

9.2 (5.5–17.5)

0.034

 Age at disease presentation, years

4.8 (3.7–7.4)

5.2 (4.1–9.5)

0.580

 Disease duration, years

7.09 ± 3.07

3.95 ± 2.1

0.008

 Female gender

9 (75)

5 (41)

0.182

Anthropometric data

 BMI, kg/m2

19.6 (14.5–30)

19.2 (15.3–25)

0.954

Body composition

 Fat percentual

28.2 (11.1–45.4)

26 (10.9–42)

0.789

 Fat mass, kg

10.8 (5.0–27.1)

8.2 (2.9–20.2)

1.000

 Lean mass, kg

26.4 (15.4–43.8)

27.2 (20–44.5)

0.423

Lipid profile

 Total cholesterol

151 (115–206)

151 (102–227)

0.913

  ≥ 170 mg/dL

5 (41)

3 (25)

0.666

 HDL, mg/dL

43 (0–65)

49 (17–72)

0.328

  ≤ 45 mg/dL

9 (75)

4 (33)

0.099

 LDL, mg/dL

92 (76–148)

77.5 (56–129)

0.265

  ≥ 130 mg/dL

1 (9)

0

1.000

 VLDL, mg/dL

16 (9–42)

14.5 (9–68)

0.957

 Triglycerides, mg/dL

82 (31–168)

72.5 (46–340)

0.935

  ≥130 mg/dL

1 (8)

3 (33)

0.316

Anti-LPL antibody

0

1 (8)

1.000

Muscle enzymes

 AST, U/L

28 (13–122)

29.5 (15–82)

0.703

 ALT, U/L

36 (22–123)

34 (29–79)

0.744

 CK, U/L

84 (33–478)

125 (62–179)

0.399

 LDH, U/L

184 (107–1234)

216.5 (153–562)

0.355

 Aldolase, U/L

5.7 (3.4–10.8)

6.35 (4.6–14.6)

0.231

Inflammatory profile

 ESR, mm/1SThour

20 (2–40)

19 (7–54)

0.624

 CRP, mg/dL

0.59 (0.16–5.5)

1.61 (0.15–26)

0.242

JDM scores

 CMAS, 0–52

52 (10–52)

52 (17–52)

0.848

 MMT, 0–80

80 (42–80)

80 (38–80)

0.742

 DAS, 0–18

4 (0–12)

3 (0–18)

0.807

 Cutaneous DAS, 0–9

1 (0–8)

1 (0–9)

0.663

 Muscle DAS

2 (0–9)

2 (0–9)

0.853

 MYOACT, 0–1

0.05 (0–0.16)

0.02 (0–0.3)

0.724

 MITAX, 0–1

0.01 (0–0.23)

0 (0–0.28)

0.462

 CHAQ

0 (0–1.75)

0.625 (0–2.5)

0.164

Treatment

 Prednisone

   

  Current use

1 (8)

8 (66)

0.303

  Cumulative dose, g

13.6 (4.9–51.5)

15.1 (3.9–31.2)

0.531

 Methotrexate

   

  Current use

3 (25)

8 (66)

0.277

  Cumulative dose, g

2.2 (0.3–16.9)

1.9 (0.37–4.98)

0.79

 Cyclosporine

   

  Current use

0

3 (25)

0.230

  Cumulative dose, g

0 (0–3.6)

0

0.805

  1. Values expressed in mean ± SD, median (range) and n (%), GBI (gingival bleeding index), BMI (body mass index), HDL (high density lipoprotein), LDL (low density lipoprotein), VLDL (very low density), anti-LPL (anti-lipoprotein lipase antibody), AST (aspartate aminotransferase), ALT (alanine aminotransferase), CK (creatine kinase), LDH (lactate dehydrogenase), ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), CMAS (Childhood Myositis Assessment Scale), MMT (Manual Muscle Testing), DAS (Disease Activity Score), MYOACT (Myositis Disease Activity Assessment Analogue Scale), MYTAX (Myositis Intention To Treat Activity Index), CHAQ (childhood assessment questionnaire)